Navigation Links
The Female Health Company to Present at Rodman & Renshaw's Annual Global Investment Conference on Wednesday, September 15, 2010
Date:9/3/2010

CHICAGO, Sept. 3 /PRNewswire/ -- The Female Health Company (Nasdaq: FHCO), which manufactures and markets the FC2 Female Condom®, today announced that the Company's CEO, O.B. Parrish, and its CFO, Donna Felch, are scheduled to make a presentation at Rodman & Renshaw's Global Investment Conference at 12:05 p.m. on Wednesday, September 15, 2010, in the Hubbard Salon, 5th floor.

The Conference will be held September 12-15, 2010 at the New York Palace Hotel in New York City.  Additional information on the Conference is available on the Internet at http://www.rodm.com/conferences?category&id=51

About Rodman & Renshaw

Rodman & Renshaw is a full-service investment banking firm that is dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies.  The firm also provides research, sales and trading services to institutional investor clients that focus on such companies.

Through its life sciences investment banking team, Rodman & Renshaw provides a broad range of investment banking services to biotechnology, specialty pharmaceutical, medical device and other companies operating in the life science space.  The team consists of seasoned professionals, many of whom have PhDs or other advanced medical or scientific degrees.  Their experience and expertise enable the firm to deliver the specialized advice and differentiated services its clients demand.

Additional information on Rodman & Renshaw is available on the Internet at www.rodmanandrenshaw.com

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and about 100 other countries around the world.  The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., Europe, Canada, Australia, South Africa, Japan, China, Spain, Greece and Turkey and are pending in various countries.  The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.  The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.  

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchanges Commission filings.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from this currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.


'/>"/>
SOURCE The Female Health Company
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
2. Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males
3. The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
4. The Female Health Company to Present at Rodman & Renshaw 10th Annual Global Investment Conference
5. New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets
6. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
7. Uckele Health & Nutrition Ranks on the 2010 Inc. 5000 List
8. maxIT Healthcare Named to Inc. 5000 List
9. BioFortis and Catholic Health Initiatives Center for Translational Research Announce Biorepository Information Technology Strategic Partnership to Drive Progress in Personalized Medicine
10. Back To School: Staying Healthy at School is as Easy as Learning Your ABCs
11. Healthcare Network Helps Fund Scholarships Totaling $15,000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CALABASAS, Calif. , Jan. 19, 2017 /PRNewswire/ ... Mathias Schmidt , Ph.D., as chief executive ... board of directors. Dr. Schmidt brings to ArmaGen more ... on the research and development of biotherapeutics and ... biopharmaceutical executive with the diverse experience and skillset ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical ... update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data ... the existing policy. AMIA recommended that NIH earmark funding for researchers to produce ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type of ... growth is accounted to two main factors. The first is the amazing customer ... vendors supplying FireflySci products all around the world. , 2016 was a tremendous sales ...
(Date:1/19/2017)... , Jan. 18, 2017 The global ... USD 92.9 billion by 2025, according to a ... industry has been adaptive of the function of ... as 2002. Among the services outsourced, clinical trial ... instance, Johnson & Johnson was the first pharmaceutical ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
Breaking Biology News(10 mins):